Valsartan, an angiotensin II type 1 receptor (AT1) antagonist, but not prazosin, an α 1-adrenergic receptor antagonist, decreased the active form of RhoA in VSMC from stroke-prone SHRs. Here, AGTR1 is linked to stroke disorder.